Terms: = Endocrine gland cancer AND MUC16, CA125, CA-125 AND Treatment
1553 results:
1. Integrated proteogenomic and metabolomic characterization of papillary thyroid cancer with different recurrence risks.
Qu N; Chen D; Ma B; Zhang L; Wang Q; Wang Y; Wang H; Ni Z; Wang W; Liao T; Xiang J; Wang Y; Jin S; Xue D; Wu W; Wang Y; Ji Q; He H; Piao HL; Shi R
Nat Commun; 2024 Apr; 15(1):3175. PubMed ID: 38609408
[TBL] [Abstract] [Full Text] [Related]
2. Efficient CAR T cell targeting of the ca125 extracellular repeat domain of muc16.
Casey NP; Kleinmanns K; Forcados C; Gelebart PF; Joaquina S; Lode M; Benard E; Kaveh F; Caulier B; Helgestad Gjerde C; García de Jalón E; Warren DJ; Lindemann K; Rokkones E; Davidson B; Myhre MR; Kvalheim G; Bjørge L; McCormack E; Inderberg EM; Wälchli S
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38604812
[TBL] [Abstract] [Full Text] [Related]
3. Sialyl-Tn serves as a potential therapeutic target for ovarian cancer.
Al-Alem L; Prendergast JM; Clark J; Zarrella B; Zarrella DT; Hill SJ; Growdon WB; Pooladanda V; Spriggs DR; Cramer D; Elias KM; Nazer RI; Skates SJ; Behrens J; Dransfield DT; Rueda BR
J Ovarian Res; 2024 Apr; 17(1):71. PubMed ID: 38566237
[TBL] [Abstract] [Full Text] [Related]
4. [Clinical analysis of 12 cases of ovarian yolk sac tumor].
Liu J; Chu HJ; Shan YP; Song WJ; Chen AP
Zhonghua Fu Chan Ke Za Zhi; 2024 Mar; 59(3):210-214. PubMed ID: 38544450
[No Abstract] [Full Text] [Related]
5. Interrogating the Theranostic Capacity of a muc16-Targeted Antibody for Ovarian cancer.
Mack KN; Samuels ZV; Carter LM; Viray TD; Mandleywala K; Brooks CL; Hollingsworth MA; Radhakrishnan P; Lewis JS
J Nucl Med; 2024 Apr; 65(4):580-585. PubMed ID: 38485271
[TBL] [Abstract] [Full Text] [Related]
6. Development of an Automatic Rule-Based Algorithm for the Detection of Ovarian cancer Recurrence From Electronic Health Records.
Lee S; Kim JH; Ha HI; Lim MC; Cho H
JCO Clin Cancer Inform; 2024 Mar; 8():e2300150. PubMed ID: 38442323
[TBL] [Abstract] [Full Text] [Related]
7. CD47-a novel prognostic predicator in epithelial ovarian cancer and correlations with clinicopathological and gene mutation features.
Luo X; Mo J; Zhang M; Huang W; Bao Y; Zou R; Yao L; Yuan L
World J Surg Oncol; 2024 Feb; 22(1):44. PubMed ID: 38317230
[TBL] [Abstract] [Full Text] [Related]
8. A study on the role of Taxifolin in inducing apoptosis of pancreatic cancer cells: screening results using weighted gene co-expression network analysis.
Chen SJ; Ren LK; Fei XB; Liu P; Wang X; Zhu CH; Pan YZ
Aging (Albany NY); 2024 Feb; 16(3):2617-2637. PubMed ID: 38305809
[TBL] [Abstract] [Full Text] [Related]
9. Targeted Mass Spectrometry of Longitudinal Patient Sera Reveals LTBP1 as a Potential Surveillance Biomarker for High-Grade Serous Ovarian Carcinoma.
Wenk D; Khan S; Ignatchenko V; May T; Bernardini MQ; Kislinger T
J Proteome Res; 2024 Feb; 23(2):749-759. PubMed ID: 38266179
[TBL] [Abstract] [Full Text] [Related]
10. Durvalumab with or without tremelimumab plus chemotherapy in HRR non-mutated, platinum-resistant ovarian cancer (KGOG 3045): A phase II umbrella trial.
Kim SI; Joung JG; Kim YN; Park J; Park E; Kim JW; Lee S; Lee JB; Kim S; Choi CH; Kim HS; Lim J; Chung J; Kim BG; Lee JY
Gynecol Oncol; 2024 Mar; 182():7-14. PubMed ID: 38246047
[TBL] [Abstract] [Full Text] [Related]
11. Ovarian clear cell carcinoma with uterine intramural recurrence: Case report of ovarian clear cell carcinoma with fertility sparing treatment.
Chang TY; Yeh CY; Yang CY; Lin WC; Huang CC; Hung YC
Taiwan J Obstet Gynecol; 2024 Jan; 63(1):90-94. PubMed ID: 38216278
[TBL] [Abstract] [Full Text] [Related]
12. Poor Concordance Between cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor.
Tjokrowidjaja A; Friedlander ML; Ledermann JA; Coleman RL; Mirza MR; Matulonis UA; Pujade-Lauraine E; Lord SJ; Scott CL; Goble S; York W; Lee CK;
J Clin Oncol; 2024 Apr; 42(11):1301-1310. PubMed ID: 38215359
[TBL] [Abstract] [Full Text] [Related]
13. Deciphering the puzzle: a case report of Tjalma syndrome (pseudo-pseudo Meigs' syndrome) with profoundly elevated ca-125 and pleural effusion.
Tan Q; Xu LF; Yan T; Huang CH; Tao Y; Huang WH; Yu SL
Front Immunol; 2023; 14():1277683. PubMed ID: 38162662
[TBL] [Abstract] [Full Text] [Related]
14. Circulating small extracellular vesicles microRNAs plus ca-125 for treatment stratification in advanced ovarian cancer.
Zhou X; Liu M; Sun L; Cao Y; Tan S; Luo G; Liu T; Yao Y; Xiao W; Wan Z; Tang J
J Transl Med; 2023 Dec; 21(1):927. PubMed ID: 38129848
[TBL] [Abstract] [Full Text] [Related]
15. [Study of the clinical significance of ETAR mRNA expression in high-grade serous ovarian cancer and the inhibitory effect of ETAR derived fusion polypeptide on cancer progression].
Zhang YL; Xia XK; Zhang M
Zhonghua Fu Chan Ke Za Zhi; 2023 Dec; 58(12):930-938. PubMed ID: 38123199
[No Abstract] [Full Text] [Related]
16. Magnetic resonance imaging for the diagnosis of malignant mixed Mullerian tumor of ovary: Two case reports.
Jin X; Zhu P; Fan S; Dai J
Medicine (Baltimore); 2023 Dec; 102(50):e36569. PubMed ID: 38115369
[TBL] [Abstract] [Full Text] [Related]
17. Digital ischaemia as a presenting feature in metastatic ovarian cancer.
Miller JH; Merry P
BMJ Case Rep; 2023 Dec; 16(12):. PubMed ID: 38061859
[TBL] [Abstract] [Full Text] [Related]
18. Serial Circulating Tumor DNA Analysis with a Tumor-Naïve Next-Generation Sequencing Panel Detects Minimal Residual Disease and Predicts Outcome in Ovarian cancer.
Heo J; Kim YN; Shin S; Lee K; Lee JH; Lee YJ; Choi Z; Park J; Min S; Kim SW; Choi JR; Kim S; Lee ST; Lee JY
Cancer Res; 2024 Feb; 84(3):468-478. PubMed ID: 38038965
[TBL] [Abstract] [Full Text] [Related]
19. Ovarian recurrence risk assessment using machine learning, clinical information, and serum protein levels to predict survival in high grade ovarian cancer.
Mysona DP; Purohit S; Richardson KP; Suhner J; Brzezinska B; Rungruang B; Hopkins D; Bearden G; Higgins R; Johnson M; Bin Satter K; McIndoe R; Ghamande S
Sci Rep; 2023 Nov; 13(1):20933. PubMed ID: 38016985
[TBL] [Abstract] [Full Text] [Related]
20. Real-world data on niraparib maintenance treatment in patients with non-gBRCA mutated platinum-sensitive recurrent ovarian cancer.
Vilming B; Fallås Dahl J; Bentzen AG; Ingebrigtsen VA; Berge Nilsen E; Vistad I; Dørum A; Solheim O; Bjørge L; Zucknick M; Aune G; Lindemann K
Int J Gynecol Cancer; 2023 Dec; 33(12):1898-1905. PubMed ID: 38000795
[TBL] [Abstract] [Full Text] [Related]
[Next]
